Myonex Joins Decentralized Trials & Research Alliance (DTRA) To Democratize And Accelerate Clinical Trials

Horsham, PA – 08/06/21


August 6, 2021 – Myonex has joined a historic alliance of over one hundred life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The “Decentralized Trials & Research Alliance (DTRA),” which launched December 2020, is uniting industry stakeholders, including healthcare companies, regulators, patient groups, and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research. 

“The reason we do what we do is to help those inflicted with disease and, through clinical research, develop new therapies that will improve their lives,” says Michael Cohen, Executive Chairman, Myonex “Joining the DTRA will allow us to contribute our expertise and discover ways to widen the reach of decentralized trials to those who need them.”    

“We are extremely gratified to welcome Myonex to the ‘Decentralized Trials & Research Alliance,’ said Amir Kalali, MD, founder of several collaborative life science communities, and co-Chair of DTRA. “By advancing decentralized research we can make the clinical trial process more patient-focused, increase trial efficiency and encourage use of technologies. We are excited by Myonex’s commitment to embracing decentralized trials and to changing the culture that has been the rate limiter to innovation.”  

Experts estimate that COVID-19 may set back non-pandemic clinical trials by several years due to prospective patients’ inability or reluctance to schedule visits at physical research locations. Decentralized approaches to conducting research facilitate participation by a more diverse patient population and could ease COVID-19-imposed difficulties for both patients and clinical investigators. Inclusion of representative patient populations in clinical trials by race, age and geographic location has long been an operational challenge.  COVID-19 has amplified the disparities and inclusion biases that have become hurdles for potential trial participants.   

“Decentralized trials are the future of clinical research and allow for a more patient-centric approach,” says Andrew Gregoire, Vice President, Business Development, Myonex. “From a clinical supplies perspective, we wanted to provide a solution for decentralized trials that benefited both the patient and the organization.”  Myonex provides a pharmacy dispensing process, Clinical Trial Prescription (CTRx) card, that gives patients access to drugs and supplies directly through their pharmacy and specialty pharmacy network in the U.S. and Canada. 

 Myonex joins with its peer DTRA Member organizations to provide expertise to identify and address gaps and needs and advance best practices through effective education and communication. If your organization is interested in joining, please visit 



Myonex is a global complete clinical trial solutions provider. For over 30 years we have been a leading global clinical trial supply company and we have expanded our service portfolio to offer complete solutions around clinical trials for our partners. We at Myonex add value to our clients by helping them always be prepared for what is next in their clinical trials. Follow Myonex on LinkedIn for more information. 



The Decentralized Trials & Research Alliance (DTRAwas convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on Twitter and LinkedIn for more information. 

Myonex News